The effects of neoadjuvant sintilimab versus pembrolizumab combined with chemotherapy on resectable non-small cell lung cancer: a multicenter propensity score-matched study
The combination of sintilimab or pembrolizumab with chemotherapy demonstrated similar effectiveness in terms of achieving a pCR in the neoadjuvant treatment of resectable NSCLC, and yielded comparable treatment outcomes.
Authors
- J. Wang
- Z. Luo
- Z. LI
- Wenjing Li (ORCID: https://orcid.org/0000-0003-2485-5735)
- Hongtao Duan (ORCID: https://orcid.org/0000-0002-8913-9628)
- Weiru Qiao
- Liping Tong
- Yichen Sun
- Xiaolong Yan
- Xiaoping Dong
- Yong Zhang
- Zhiyuan Gao
- Xian Chen
Institutions
- Chongqing Medical University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-aw-1256
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00